Caroline A. Grady*, Madsen Beau de Rochars†, Abdel N. Direny†, Jean Nicolas Orelus†, Joyanna Wendt*, Jeanne Radday*, Els Mathieu*, Jacquelin M. Roberts*, Thomas G. Streit‡, David G. Addiss*, and Patrick J. Lammie*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Hopital Ste. Croix, Leogane, Haiti; ‡University of Notre Dame, Notre Dame, Indiana, USA;
Figure 1. Microfilaremia prevalence determined by screening thick blood films before and 6–9 months after annual mass drug administration in sentinel sites in Leogane Commune, Haiti. Blood samples (20 μL) were collected from 7–9 PM.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.